Unite for MM: Linking Insights for MM Patient Care

The Unite for MM initiative was developed by a steering committee that included representatives from across the multiple myeloma (MM) community, and surveyed over 2000 patients and health care professionals (HCPs) about their challenges with relapsed/refractory multiple myeloma (RRMM)¹

Patients and HCPs have different priorities when it comes to RRMM treatments, and these treatments can place a heavy toll on patients
Many patients, including non-White patients,^a also lack awareness of recently approved immunotherapies, or have not been offered these treatments

^aRacial data available only for patients in the US.¹

Style

Linking-it-banner, top-header-margin

Key Findings and Actions to Consider Developed in Partnership With the Steering Committee

Different HCP–Patient Treatment Decision-Making Priorities¹

Call to Action

Collaborate to Relieve Treatment-Related Burdens and Identify Patient Treatment Goals

Differing Opinions on the Most Challenging Side Effects¹

Call to Action

Reduce Treatment Burdens by Using a Comprehensive Approach to Manage Side Effects

Low Patient Awareness of and Confidence in Bispecific Antibodies and Chimeric Antigen Receptor T-Cell Therapies¹

Call to Action

Improve Patient Familiarity With Recently Approved Immunotherapies

Style

Finding-actions

Practical and educational/experience challenges to immunotherapy use¹

Call to Action

Increase HCP Familiarity With Recently Approved Immunotherapies

Call to Action

Reduce Barriers to the Adoption of Recently Approved Immunotherapies

Access the survey publication to deepen your understanding of key insights

Style

Prac-edu

Access Additional Resources^a

Tools to help people with cancer live life beyond their diagnosis

Educational resources on MM care and research initiatives

Patient support organizations providing educational, access, and research information

^aThe organization names and logos are for external link attribution only and do not imply endorsement by the respective organizations.

Style

Access-res

Female doctor and an older female patient reviewing a tablet whilst smiling., Picture

By encouraging conversations between patients and HCPs, increasing education, decreasing logistic burdens, gathering data, and strengthening links between members of the MM community, Pfizer hopes to optimize care and improve patient outcomes.

Pfizer thanks the Steering Committee, as well as the HCPs and patients who responded to the surveys and helped collect these valuable data.

Style

Pg-break

Reference

Ailawadhi S, Biru Y, Clavreul S, et al. Perspectives of healthcare providers and patients with relapsed/refractory multiple myeloma on treatment priorities and novel therapies. Patient Prefer Adherence. 2025;2025(19):1089-1104. Published April 2, 2025. Taylor & Francis Ltd. Reprinted by permission of the publisher Informa UK Limited trading as Taylor & Francis Ltd, http://www.tandfonline.com.

Style

references